Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients,Journal of the National Cancer Institute

当前位置： X-MOL 学术 › J. Natl. Cancer Inst. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2018-03-05 , DOI: 10.1093/jnci/djy022
Pauline Depuydt _{1,

2} , Valentina Boeva _{3,

4} , Toby D Hocking ₅ , Robrecht Cannoodt _{1,

2,

6} , Inge M Ambros _{7,

8} , Peter F Ambros _{7,

8} , Shahab Asgharzadeh ₉ , Edward F Attiyeh _{10,

11,

12} , Valérie Combaret ₁₃ , Raffaella Defferrari ₁₄ , Matthias Fischer _{15,

16} , Barbara Hero ₁₇ , Michael D Hogarty _{10,

18} , Meredith S Irwin ₁₉ , Jan Koster ₂₀ , Susan Kreissman ₂₁ , Ruth Ladenstein _{7,

8} , Eve Lapouble _{22,

23} , Geneviève Laureys ₂₄ , Wendy B London ₂₅ , Katia Mazzocco ₁₄ , Akira Nakagawara ₂₆ , Rosa Noguera _{27,

28,

29} , Miki Ohira ₃₀ , Julie R Park ₃₁ , Ulrike Pötschger ₇ , Jessica Theissen ₁₅ , Gian Paolo Tonini ₃₂ , Dominique Valteau-Couanet ₃₃ , Luigi Varesio ₃₄ , Rogier Versteeg ₂₀ , Frank Speleman _{1,

2} , John M Maris _{10,

11,

12,

35,

36} , Gudrun Schleiermacher ₃₇ , Katleen De Preter _{1,

2}

Affiliation

Center for Medical Genetics, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent, Ghent, Belgium.
Institut Cochin, Inserm U1016, CNRS UMR 8104, Université Paris Descartes UMR-S1016, Paris, France.
Institut Curie, Inserm U900, Mines ParisTech, PSL Research University, Paris, France.
Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Data Mining and Modelling for Biomedicine Group, VIB Center for Inflammation Research, Ghent, Belgium.
Children's Cancer Research Institute, Austria.
Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
Division of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA.
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Center for Childhood Cancer Research, University of Pennsylvania, Philadelphia, PA.
Department of Pediatrics, University of Pennsylvania, Philadelphia, PA.
Centre Léon-Bérard, Laboratoire de Recherche Translationnelle, Lyon, France.
Department of Pathology, Istituto Giannina Gaslini, Genova, Italy.
Department of Experimental Pediatric Oncology, University of Cologne, Cologne, Germany.
University Children's Hospital Cologne, Medical Faculty, and Center for Molecular Medicine Cologne.
Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany.
Perelman School of Medicine (MDH), University of Pennsylvania, Philadelphia, PA.
Division of Hematology-Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Department of Pediatrics, Duke University School of Medicine, Durham, NC.
Genetic Somatic Unit.
Institut Curie, Paris, France.
Department of Pediatric Hematology and Oncology, Ghent University Hospital, De Pintelaan, Ghent, Belgium.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.
Saga Medical Center KOSEIKAN, Saga, Japan.
Pathology Department, Medical School, University of Valencia, Valencia, Spain.
Medical Research Foundation INCLIVA, Valencia, Spain.
CIBERONC, Madrid, Spain.
Research Institute for Clinical Oncology Saitama Cancer Center, Saitama, Japan.
Seattle Children's Hospital and University of Washington, Seattle, WA.
Laboratory of Neuroblastoma, Onco/Haematology Laboratory, University of Padua, Pediatric Research Institute (IRP)-Città della Speranza, Padova, Italy.
Institut Gustave Roussy, Université Paris Sud, Paris, France.
Laboratory of Molecular Biology (LV), Istituto Giannina Gaslini, Genova, Italy.
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abramson Family Cancer Research Institute, Philadelphia, PA.
U830 INSERM, Recherche Translationelle en Oncologie Pédiatrique (RTOP) and Department of Pediatric Oncology.

Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, particularly in low- and intermediate-risk neuroblastoma patients. To improve outcome prediction in high-risk neuroblastoma, we aimed to design a prognostic classification method based on copy number aberrations.

中文翻译：

基因组扩增和远端 6q 丢失：高危神经母细胞瘤患者生存不良的新标志物

神经母细胞瘤的特点是大量临床异质性。尽管进行了强化治疗，但高危神经母细胞瘤患者的存活率仍然低得令人失望。已显示体细胞染色体拷贝数异常与患者预后相关，尤其是在低风险和中风险神经母细胞瘤患者中。为了改善高危神经母细胞瘤的结果预测，我们旨在设计一种基于拷贝数畸变的预后分类方法。

更新日期：2018-03-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文